{
  "disease": "stroke",
  "items": [
    {
      "source": "pubmed",
      "pmid": "41678809",
      "doi": "10.1212/WNL.0000000000214702",
      "title": "IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion.",
      "abstract": "The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82];  Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41678809/",
      "summary_ja": "背景：大血管閉塞による脳卒中患者に対し、血管内血栓除去術（EVT）前のアルテプラーゼによる静脈内血栓溶解療法（IVT）の効果は限定的かつ時間依存的である。代替薬として推奨されるテネクテプラーゼのデータは不足している。  \n方法：発症から4.5時間以内の前方循環大血管閉塞脳卒中患者を対象に、テネクテプラーゼ併用EVT（TNK + EVT）群とEVT単独群の2つの全国実臨床レジストリを用いた後ろ向きプール解析を実施。3か月後の改訂Rankinスケール（mRS）を主要評価項目とし、傾向スコア重み付けロジスティック回帰で群間比較を行った。  \n結果：1,890例（TNK + EVT：798例、EVT：1,092例、中央値年齢73歳）を解析。TNK + EVT群は全mRSスコアで有意に良好な機能的転帰を示し（加重共通オッズ比1.53、95%CI 1.29-1.82）、安全性に問題は認められなかった。効果は治療時間に依存しなかった。  \n結論：発症早期の大血管閉塞脳卒中において、EVT前のテネクテプラーゼ静注はEVT単独よりも3か月後の機能的予後を改善し、安全に使用可能であることが示された。",
      "summary_short_ja": "前向き脳梗塞患者を対象に、IVテネクテプラーゼ（TNK）併用血栓回収療法（EVT）とEVT単独の効果を比較した後ろ向き解析で、TNK+EVT群は3か月後の機能的回復が有意に良好であった。治療開始から4.5時間以内の症例で安全性に問題はなく、効果は時間依存性が認められなかった。これにより、早期脳梗塞治療におけるTNK併用の有用性が示された。",
      "disease": "stroke",
      "section": "imaging"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "背景：前治療としての抗血小板療法（APT）が、前方循環大血管閉塞（LVO）急性虚血性脳卒中に対する直接血管内治療（EVT）の成績に与える影響は不明瞭であり、臨床的利益や安全性に関するエビデンスは限られている。  \n方法：2015～2023年に欧州9カ国とイスラエルの20施設で施行されたEVA-TRISPレジストリから、静脈内血栓溶解療法や抗凝固療法を受けていない前方循環LVO脳卒中患者2,611例を対象に後ろ向き解析を行い、前治療APTの有無で1,308例を傾向スコアマッチングした。主要評価項目は90日後の修正Rankinスケール（mRS）、副次評価項目は90日後の自立度、再灌流成功率、症候性頭蓋内出血（sICH）発生率、死亡率とした。  \n結果：平均年齢75.8歳、NIHSSスコア13.1点、再灌流成功率74.7%、90日後自立率38.8%であった。APT既往群は非APT群に比べ、90日mRSが有意に改善（オッズ比1.30、95%CI 1.04-1.61）し、自立度も高かったが、sICHリスクの増加は認められなかった。  \n結論：前治療APTは、直接EVTを受ける前方循環LVO脳卒中患者において、90日後の機能的予後改善および自立度向上と関連し、安全性にも問題はなかった。",
      "summary_short_ja": "前治療として抗血小板療法（APT）を受けていた前向き脳梗塞患者（前方循環大血管閉塞）に対し、直接血管内治療（EVT）を行った結果を多施設で後ろ向き解析した。APT既往群は90日後の機能的予後（修正Rankinスケール）や自立度が有意に良好で、症候性頭蓋内出血リスクの増加は認められなかった。APT既往は直接EVT治療患者の予後改善に寄与する可能性が示された。",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "背景：前治療としての抗血小板療法（APT）が、前方循環大血管閉塞（LVO）急性虚血性脳卒中に対する直接血管内治療（EVT）の成績に与える影響は不明瞭であり、臨床的利益や安全性に関するエビデンスは限られている。  \n方法：2015～2023年に欧州9カ国とイスラエルの20施設で施行されたEVA-TRISPレジストリから、静脈内血栓溶解療法や抗凝固療法を受けていない前方循環LVO脳卒中患者2,611例を対象に後ろ向き解析を行い、前治療APTの有無で1,308例を傾向スコアマッチングした。主要評価項目は90日後の修正Rankinスケール（mRS）、副次評価項目は90日後の自立度、再灌流成功率、症候性頭蓋内出血（sICH）発生率、死亡率とした。  \n結果：平均年齢75.8歳、NIHSSスコア13.1点、再灌流成功率74.7%、90日後自立率38.8%であった。APT既往群は非APT群に比べ、90日mRSが有意に改善（オッズ比1.30、95%CI 1.04-1.61）し、自立度も高かったが、sICHリスクの増加は認められなかった。  \n結論：前治療APTは、直接EVTを受ける前方循環LVO脳卒中患者において、90日後の機能的予後改善および自立度向上と関連し、安全性にも問題はなかった。",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "背景：前治療としての抗血小板療法（APT）が、前方循環大血管閉塞（LVO）急性虚血性脳卒中に対する直接血管内治療（EVT）の成績に与える影響は不明瞭であり、臨床的利益や安全性に関するエビデンスは限られている。  \n方法：2015～2023年に欧州9カ国とイスラエルの20施設で施行されたEVA-TRISPレジストリから、静脈内血栓溶解療法や抗凝固療法を受けていない前方循環LVO脳卒中患者2,611例を対象に後ろ向き解析を行い、前治療APTの有無で1,308例を傾向スコアマッチングした。主要評価項目は90日後の修正Rankinスケール（mRS）、副次評価項目は90日後の自立度、再灌流成功率、症候性頭蓋内出血（sICH）発生率、死亡率とした。  \n結果：平均年齢75.8歳、NIHSSスコア13.1点、再灌流成功率74.7%、90日後自立率38.8%であった。APT既往群は非APT群に比べ、90日mRSが有意に改善（オッズ比1.30、95%CI 1.04-1.61）し、自立度も高かったが、sICHリスクの増加は認められなかった。  \n結論：前治療APTは、直接EVTを受ける前方循環LVO脳卒中患者において、90日後の機能的予後改善および自立度向上と関連し、安全性にも問題はなかった。",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "背景：前治療としての抗血小板療法（APT）が、前方循環大血管閉塞（LVO）急性虚血性脳卒中に対する直接血管内治療（EVT）の成績に与える影響は不明瞭であり、臨床的利益や安全性に関するエビデンスは限られている。  \n方法：2015～2023年に欧州9カ国とイスラエルの20施設で施行されたEVA-TRISPレジストリから、静脈内血栓溶解療法や抗凝固療法を受けていない前方循環LVO脳卒中患者2,611例を対象に後ろ向き解析を行い、前治療APTの有無で1,308例を傾向スコアマッチングした。主要評価項目は90日後の修正Rankinスケール（mRS）、副次評価項目は90日後の自立度、再灌流成功率、症候性頭蓋内出血（sICH）発生率、死亡率とした。  \n結果：平均年齢75.8歳、NIHSSスコア13.1点、再灌流成功率74.7%、90日後自立率38.8%であった。APT既往群は非APT群に比べ、90日mRSが有意に改善（オッズ比1.30、95%CI 1.04-1.61）し、自立度も高かったが、sICHリスクの増加は認められなかった。  \n結論：前治療APTは、直接EVTを受ける前方循環LVO脳卒中患者において、90日後の機能的予後改善および自立度向上と関連し、安全性にも問題はなかった。",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "背景：前治療としての抗血小板療法（APT）が、前方循環大血管閉塞（LVO）急性虚血性脳卒中に対する直接血管内治療（EVT）の成績に与える影響は不明瞭であり、臨床的利益や安全性に関するエビデンスは限られている。  \n方法：2015～2023年に欧州9カ国とイスラエルの20施設で施行されたEVA-TRISPレジストリから、静脈内血栓溶解療法や抗凝固療法を受けていない前方循環LVO脳卒中患者2,611例を対象に後ろ向き解析を行い、前治療APTの有無で1,308例を傾向スコアマッチングした。主要評価項目は90日後の修正Rankinスケール（mRS）、副次評価項目は90日後の自立度、再灌流成功率、症候性頭蓋内出血（sICH）発生率、死亡率とした。  \n結果：平均年齢75.8歳、NIHSSスコア13.1点、再灌流成功率74.7%、90日後自立率38.8%であった。APT既往群は非APT群に比べ、90日mRSが有意に改善（オッズ比1.30、95%CI 1.04-1.61）し、自立度も高かったが、sICHリスクの増加は認められなかった。  \n結論：前治療APTは、直接EVTを受ける前方循環LVO脳卒中患者において、90日後の機能的予後改善および自立度向上と関連し、安全性にも問題はなかった。",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "published": "2026-Mar-24",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671526",
      "doi": "10.1212/WNL.0000000000214672",
      "title": "Previous Antiplatelet Therapy and Outcomes of Acute Ischemic Stroke With Large Vessel Occlusion Treated With Direct Endovascular Therapy.",
      "abstract": "Previous antiplatelet therapy (APT) may influence outcomes in patients undergoing direct endovascular therapy (EVT) for anterior circulation large vessel occlusion (LVO) stroke, but evidence on clinical benefits and safety is limited and inconsistent. We aimed to evaluate the effects of previous APT on the outcomes of direct EVT. We conducted a retrospective analysis of consecutive patients treated at 20 high-volume stroke centers across 9 European countries and Israel (EVA-TRISP registry, 2015-2023). We included adults with anterior circulation LVO strokes, without previous use of IV thrombolysis (IVT) or anticoagulants. We compared outcomes of direct EVT patients stratified by previous APT regimen, using propensity score matching based on medical history and multilevel models to address confounders. The primary outcome was the 90-day modified Rankin Scale (mRS) score. The secondary efficacy outcomes were 90-day independence and the rate of successful reperfusion. The secondary safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) and mortality. Among 12,950 patients, 2,611 met the criteria and 1,308 were matched: 480 without previous APT and 828 with any previous APT, among whom 764 were on single APT and 64 on dual APT. The overall mean age was 75.8 ± 11.4 years, and 49.4% were female; the mean NIH Stroke Scale score was 13.1 ± 7.2 points, the successful reperfusion rate was 74.7%, and the median mRS score was 3 (interquartile range 2-4), with 38.8% of patients independent at 90 days. When compared with no previous APT, any previous APT was associated with a shift toward lower mRS scores at 90 days (odds ratio [OR] 1.30, CI 1.04-1.61,  In patients with anterior circulation LVO stroke treated with direct EVT and no previous anticoagulation, pretreatment with any APT was independently linked to better 90-day functional outcomes and higher independence, without increasing sICH risk. This study provides Class III evidence that, in patients with anterior circulation LVO stroke treated with direct EVT, previous APT is associated with better 90-day functional outcomes compared with no previous APT.",
      "journal": "Neurology",
      "year": "2026",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671526/",
      "summary_ja": "",
      "disease": "stroke",
      "section": "diagnosis"
    },
    {
      "source": "pubmed",
      "pmid": "41671519",
      "doi": "10.1212/WNL.0000000000214677",
      "title": "Associations of Lifetime Cognitive Enrichment With Incident Alzheimer Disease Dementia, Cognitive Aging, and Cognitive Resilience.",
      "abstract": "The effects of lifetime cognitive enrichment on later-life cognitive outcomes are not comprehensively investigated. The aim of this study was to test the association of lifetime cognitive enrichment with Alzheimer disease (AD) dementia and cognitive decline and in an autopsied deceased subset to explore the association between lifetime enrichment and AD and related dementia (ADRD) pathologic indices and cognitive resilience that is, decline after adjusting for common ADRD pathologies. This was a longitudinal clinicopathologic study involving older individuals from Northeastern Illinois who participated in the Rush Memory and Aging Project, were free of dementia at baseline, completed surveys reflecting lifetime enrichment, and had annual clinical evaluations. We constructed a composite measure reflecting lifetime cognitive enrichment and tested its association with incident AD dementia in proportional hazards models, mean age of AD dementia onset in an accelerated failure time model, and cognitive decline using linear mixed-effects models. In a deceased subset, we tested the association of lifetime cognitive enrichment with 9 ADRD pathologies and cognitive resilience. Participants (n = 1,939, 75% female, mean baseline age = 79.6) completed an average of 7.6 years of follow-up, during which 551 participants developed AD dementia. One unit higher in lifetime enrichment was associated with 38% lower hazards of developing AD dementia (hazard ratio 0.62, 95% CI 0.52-0.73,  Lifetime exposure to cognitive enrichment was related to lower risk of AD dementia and a slower rate of cognitive decline, including after adjustment for common ADRD pathologies, indicating higher resilience provided by lifetime enrichment. Our results suggest that cognitive health in later life is in part the product of lifetime exposure to cognitive enrichment.",
      "journal": "Neurology",
      "year": "2026",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41671519/",
      "summary_ja": "",
      "disease": "stroke",
      "section": "imaging"
    }
  ]
}